All In Biotech

Drug Trial Radar · NCT07191483

A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of KYN-5356 as Adjunctive Treatment in Adults With Cognitive Impairment Associated With Schizophrenia

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 149 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

149

Actual

Start

Aug 27, 2025

Primary completion

Sep 9, 2026

Study completion Sep 16, 2026

Sponsor

Lead sponsor
Kynexis B.V.Industry
Sponsor type
Industry
First posted
Sep 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 and placebo for 28 days. Participants will be randomized to one of 4 treatment groups: placebo, KYN-5356 low dose, KYN-5356 medium dose, KYN-5356 high dose. Participants will be admitted to the clinic on Day -3 and will remain in residence at the clinic for 32 days, from baseline through the treatment period. Participants will be administered investigational medicinal product on Days 1 through 28. Efficacy, safety, PK and exploratory PD assessments will be performed throughout the dosing period. Participants will be discharged on Day 29 after safety assessments are completed and return for a follow-up visit on Day 42. A subset of participants from selected sites will undergo electrophysiological assessments to evaluate the effect of KYN-5356 on neurophysiological measures of brain function.

Conditions

  • Cognitive Impairment Associated With Schizophrenia (CIAS)

Interventions

  • KYN-5356 low doseDrug

    oral tablet

  • PlaceboOther

    Oral tablet

  • KYN-5356 Medium DoseDrug

    oral tablet

  • KYN-5356 High DoseDrug

    oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of KYN-5356 treatment on cognitive function in adults with cognitive impairment associated with schizophrenia (CIAS)Time frame: 28 days

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Woodland International Research Group

    Little Rock, Arkansas

  • Synapse Clinical Trials

    Cerritos, California

  • Synergy Research Center

    Lemon Grove, California

  • Cenexel CNS

    Los Alamitos, California

  • NeuroBehavioral Hospitals of the Palm Beaches - South

    Boynton Beach, Florida

  • Cenexel RCA

    Hollywood, Florida

  • Segal Trials

    Miami Lakes, Florida

  • Cenexel ACMR

    Atlanta, Georgia

  • Cenexel iResearch Atlanta

    Decatur, Georgia

  • Uptown Research Institute

    Chicago, Illinois

  • Cenexel CBH

    Gaithersburg, Maryland

  • Arch Clinical Trials

    St Louis, Missouri

  • Cenexel HRI

    Marlton, New Jersey

  • Neuro-Behavioral Clinical Research

    North Canton, Ohio

  • Community Clinical Research

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.